RT Journal Article
T1 Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists.
A1 Sánchez-Rovira, Pedro
A1 Zamora, Pilar
A1 Salvador-Bofill, Javier
A1 Morales, Serafín
A1 Martínez-Jáñez, Noelia
A1 Martínez-de-Dueñas, Eduardo
A1 Lluch, Ana
A1 Illarramendi, José Juan
A1 Gómez-Pardo, Patricia
A1 Gavilá Gregori, Joaquín
A1 García-Palomo, Andrés
A1 García-Mata, Jesús
A1 Fernández, Yolanda
A1 Del Barco, Sonia
A1 de Juan, Ana
A1 Ciruelos, Eva
A1 Chacón, José Ignacio
A1 Calvo, Lourdes
A1 Barnadas, Agustí
A1 Albanell, Joan
K1 HER2 receptor
K1 Metastatic breast cancer
K1 chemotherapy
K1 clinical practice
K1 hormone therapy
K1 survey
K1 triple negative tumor
AB Objective: The aim of this survey conducted by 20 leading Spanish oncologists was to analyze the concurrence between Spanish clinical practice and the recently published definition of the optimal sequence for the systemic treatment of metastatic breast cancer (MBC) according to patient profiles. Methods: A self-administered questionnaire was developed, divided into five sections comprising 34 specific questions related to sequential treatments, plus three additional general questions. Respondents were asked to justify negative answers. Participants were recruited randomly by invitation out of a total of 619 oncologists. The questionnaire was sent and collected via e-mail between October 2015 and May 2016. A total of 191 completed questionnaires were received. Results: Overall, 70% of oncologists would keep the three patient profiles exactly as proposed (hormone receptor-positive and HER2-negative, HER2-positive, and triple negative breast cancer). Affirmative answers to questions regarding treatment sequences for these patient profiles (1-34) ranged from 77.8-99.5%, with an average of 90.9% of oncologists being in agreement with the recommended sequential treatments. The lowest degree of consensus was observed for endocrine treatments in pre-menopausal women and for chemotherapy options in hormone-resistant patients, whilst the highest degree of consensus was reached for targeted therapies in HER2-positive patients and for endocrine therapy in post-menopausal women. In their comments, participants revealed a number of economic constraints that prevented them from implementing some of the best treatment options. Conclusions: In conclusion, despite the complexity of MBC treatment, there is general agreement on the optimal treatment sequences.
SN 2155-6660
YR 2019
FD 2019-04-08
LK https://hdl.handle.net/10668/25395
UL https://hdl.handle.net/10668/25395
LA en
DS RISalud
RD Apr 10, 2025